SPRY vs TLRY

For growth investors, Tilray Brands, Inc.

(TLRY) is the stronger pick with 4. 8% revenue growth year-over-year, versus -5. 5% for ARS Pharmaceuticals, Inc. (SPRY). Analysts rate ARS Pharmaceuticals, Inc. (SPRY) a "Hold" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Tilray Brands, Inc.

(TLRY) delivered a total return of -65. 0%, compared to -68. 0% for ARS Pharmaceuticals, Inc. (SPRY). Over 10 years, the gap is even starker: SPRY returned -65. 0% versus TLRY's -75. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ARS Pharmaceuticals, Inc.

(SPRY) is the lower-risk stock at 1. 47β versus Tilray Brands, Inc. 's 2. 04β — meaning TLRY is approximately 38% more volatile than SPRY relative to the S&P 500.

By revenue growth (latest reported year), Tilray Brands, Inc.

(TLRY) is pulling ahead at 4. 8% versus -5. 5% for ARS Pharmaceuticals, Inc. (SPRY). On earnings-per-share growth, the picture is similar: Tilray Brands, Inc. grew EPS -651. 7% year-over-year, compared to -23. 3% for ARS Pharmaceuticals, Inc.. Over a 3-year CAGR, SPRY leads at 300. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ARS Pharmaceuticals, Inc.

(SPRY) is the more profitable company, earning -203. 3% net margin versus -266. 3% for Tilray Brands, Inc. — meaning it keeps -203. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SPRY leads at -212. 9% versus -277. 9% for TLRY. At the gross margin level — before operating expenses — SPRY leads at 54. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, ARS Pharmaceuticals, Inc.

(SPRY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Tilray Brands, Inc. (TLRY) carries a higher beta of 2. 04 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SPRY: -65. 0%, TLRY: -75. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.